Related Experiment Video
Updated: Mar 27, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Neoadjuvant targeted therapies in renal cell carcinoma]
P Bigot1, G Pignot2, J-C Bernhard3
1Service d'urologie, CHU d'Angers, 2, rue Moll, 49000 Angers, France; Réseau français de recherche sur le cancer du rein UroCCR, service de chirurgie urologique, CHU de Bordeaux, place Amélie Raba-Léon, 33076 Bordeaux cedex, France.
Introduction:
Targeted molecules are used in the treatment of metastatic kidney cancer. Their use before surgery could reduce tumor volume, facilitate surgical resection and treat micrometastases. In this literature review, we present the main results of studies that evaluated the benefit of targeted therapies in kidney cancer.
Methods:
This article is based on a systematic literature search by using Pubmed database.
Results:
In prospective studies, a decrease in the size of the primary tumor has been reported to be 9.6 to 28.3%. In case of metastatic kidney cancer, cytoreductive nephrectomy could be possible after targeted therapies in tumors that initially were not available for surgery. In localized kidney cancer, a reduction of tumor volume of more than 30% is obtained in 5 to 45% of cases after neoadjuvant targeted therapies. Their use is associated with the occurrence of the usual side effects of targeted therapies plus a specific risk of delayed healing and metastatic progression during the perioperative period. The study of tumors after surgery shows a lower efficiency of the production of tumor necrosis in non-clear cell carcinomas.
Conclusion:
Data from the literature are not currently in favor of neoadjuvant use of targeted therapies in the treatment of kidney cancer. Prospective studies will be required to determine their interest in the prevention of metastatic recurrence after surgery.
Insights
Neoadjuvant targeted therapies show potential in reducing kidney cancer tumor size, but current data do not support their routine use before surgery due to side effects and lack of proven benefit in preventing recurrence.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Targeted therapies are utilized in metastatic kidney cancer treatment.
- Pre-operative targeted therapy may reduce tumor volume and aid surgical resection.
- Evaluating targeted therapies for kidney cancer is crucial.
Purpose of the Study:
- To review studies on the benefits of targeted therapies in kidney cancer.
- To assess the efficacy of neoadjuvant targeted therapies.
- To understand the impact on tumor volume and surgical outcomes.
Main Methods:
- Systematic literature search conducted.
- PubMed database was utilized for the search.
- Analysis of prospective studies on targeted therapies in kidney cancer.
Main Results:
- Tumor size reduction observed in prospective studies (9.6-28.3%).
- Neoadjuvant targeted therapies can enable cytoreductive nephrectomy in some metastatic cases.
- Localized kidney cancer shows >30% volume reduction in 5-45% of cases; associated with side effects and perioperative risks.
Conclusions:
- Current literature does not favor neoadjuvant targeted therapies for kidney cancer.
- Further prospective studies are needed to evaluate their role in preventing post-surgical metastatic recurrence.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:27Tumor Immunotherapy
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers